Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 8/20 | 0.59 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.59 |
| ▸ | HTR2C | P28335 | 3/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.59 |
| ▸ | DRD2 | P14416 | 15/20 | 0.59 |
| ▸ | HTR1A | P08908 | 4/20 | 0.59 |
| ▸ | DRD3 | P35462 | 10/20 | 0.58 |
| ▸ | DRD4 | P21917 | 5/20 | 0.58 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.53 |
| ▸ | FAAH | O00519 | 1/20 | 0.52 |
| ▸ | CNR1 | P21554 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13399454 | 0.80 | DRD3 (0.70) | SLC6A4DRD2DRD3DRD4SLC6A2 | |
| SCHEMBL13398933 | 0.79 | DRD3 (0.75) | DRD2DRD3DRD4FAAHCNR1 | |
| SCHEMBL21997329 | 0.78 | SIGMAR1 (0.50) | — | |
| SCHEMBL21997547 | 0.77 | ACKR3 (0.48) | HTR2AOPRM1 | |
| SCHEMBL20927229 | 0.75 | SIGMAR1 (0.42) | — | |
| SCHEMBL12441232 | 0.74 | HTR2A (1.00) | HTR2ASLC6A4HTR2CKCNH2DRD2 | |
| SCHEMBL28972649 | 0.74 | DRD2 (1.00) | HTR2ASLC6A4HTR2CKCNH2DRD2 | |
| SCHEMBL28972650 | 0.74 | DRD2 (1.00) | HTR2ASLC6A4HTR2CKCNH2DRD2 | |
| SCHEMBL1491196 | 0.74 | DRD2 (0.68) | HTR2ASLC6A4DRD2HTR1ADRD3 | |
| SCHEMBL1078584 | 0.73 | HTR2A (0.72) | HTR2ASLC6A4HTR2CKCNH2DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895558-B2 | Arylpiperazine-containing pyrrole 3-carboxamide derivatives for treating depressive disorders | GREEN CROSS CORPORATION (KR) | 2014-11-25 | — | — | US | disclosed |
| US-8895558-B2 | Arylpiperazine-containing pyrrole 3-carboxamide derivatives for treating depressive disorders | GREEN CROSS CORPORATION (KR) | 2014-11-25 | — | — | US | disclosed |
| US-8785453-B2 | Arylpiperazine-containing purine derivatives and uses thereof | GREEN CROSS CORPORATION (KR) | 2014-07-22 | — | — | US | disclosed |
| US-8785453-B2 | Arylpiperazine-containing purine derivatives and uses thereof | GREEN CROSS CORPORATION (KR) | 2014-07-22 | — | — | US | disclosed |
| US-20120232090-A1 | ARYLPIPERAZINE-CONTAINING PURINE DERIVATIVES AND USES THEREOF | GREEN CROSS CORPORATION (KR) | 2012-09-13 | — | — | US | disclosed |
| US-20120232090-A1 | ARYLPIPERAZINE-CONTAINING PURINE DERIVATIVES AND USES THEREOF | GREEN CROSS CORPORATION (KR) | 2012-09-13 | — | — | US | disclosed |
| US-20110178091-A1 | ARYLPIPERAZINE-CONTAINING PYRROLE 3-CARBOXAMIDE DERIVATIVES FOR TREATING DEPRESSIVE DISORDERS | GREEN CROSS CORPORATION (KR) | 2011-07-21 | — | — | US | disclosed |
| US-20110178091-A1 | ARYLPIPERAZINE-CONTAINING PYRROLE 3-CARBOXAMIDE DERIVATIVES FOR TREATING DEPRESSIVE DISORDERS | GREEN CROSS CORPORATION (KR) | 2011-07-21 | — | — | US | disclosed |
| WO-2011059207-A2 | ARYLPIPERAZINE-CONTAINING PURINE DERIVATIVES AND USES THEREOF | GREEN CROSS CORPORATION (KR) | 2011-05-19 | — | — | WO | disclosed |
| WO-2010038948-A2 | ARYLPIPERAZINE-CONTAINING PYRROLE 3-CARBOXAMIDE DERIVATIVES FOR TREATING DEPRESSIVE DISORDERS | GREEN CROSS CORPORATION (KR) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178091-A1 | ARYLPIPERAZINE-CONTAINING PYRROLE 3-CARBOXAMIDE DERIVATIVES FOR TREATING DEPRESSIVE DISORDERS | NPY5R, TPH2, MC5R | HTR2A 18/4885SLC6A4 111/4885HTR2C 10/4885 |
| US-20120232090-A1 | ARYLPIPERAZINE-CONTAINING PURINE DERIVATIVES AND USES THEREOF | ADORA2A, P2RX5, PNP | HTR2A 17/4885SLC6A4 76/4885HTR2C 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.